APA (7th ed.) Citation

Koch, C., Waldschmidt, D., Goetze, T., Ehmer, U., Ertl, S., Schmidt, H., . . . Trojan, J. (2025). 1502P CaboRISE (AIO-HEP-0320/ass.): A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function. Annals of Oncology, 36, S901. https://doi.org/10.1016/j.annonc.2025.08.2132

Chicago Style (17th ed.) Citation

Koch, C., et al. "1502P CaboRISE (AIO-HEP-0320/ass.): A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients with Preserved Liver Function." Annals of Oncology 36 (2025): S901. https://doi.org/10.1016/j.annonc.2025.08.2132.

MLA (9th ed.) Citation

Koch, C., et al. "1502P CaboRISE (AIO-HEP-0320/ass.): A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib as Second-line Therapy for Advanced HCC in Patients with Preserved Liver Function." Annals of Oncology, vol. 36, 2025, p. S901, https://doi.org/10.1016/j.annonc.2025.08.2132.